a stronger push to offer drug therapy for primary prevention of breast cancer in higher-risk women
September 2013
You'll see a stronger push to offer drug therapy for primary prevention of breast cancer in higher-risk women.
Tamoxifen and raloxifene are approved for prevention in women with a 5-year risk of breast cancer ≥ 1.66%...about the risk of an average woman over 60.
But age alone usually isn't enough to start drug therapy. Benefits generally don't outweigh risks unless the woman also has a family history of breast cancer, atypical hyperplasia, or other risks.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote